

ABSTRACT OF THE DISCLOSURE

This invention is related to novel cyclopentyl derivatives of the following general Formula (I), wherein X is methylene, oxygen, sulphur or a NR^7 group; R^1 is a straight or branched $\text{C}_1\text{-C}_8$ alkyl or $\text{C}_3\text{-C}_8$ alkenylene or $\text{C}_3\text{-C}_8$ alkynylene chain, optionally substituted with CF_3 , phenyl, phenoxy or naphthyl, the aromatic rings optionally substituted by one or more $\text{C}_1\text{-C}_4$ alkyl, halogens, trifluoromethyl, hydroxy or $\text{C}_1\text{-C}_4$ alkoxy groups; R^2 , R^3 are independently hydrogen, a $\text{C}_1\text{-C}_3$ alkyl chain, halogen, trifluoromethyl, hydroxy or $\text{C}_1\text{-C}_4$ alkoxy groups; R^4 , R^5 , R^6 , R^7 are independently hydrogen or $\text{C}_1\text{-C}_6$ alkyl; and the pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefor useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.